Diabetic Foot Ulcer
Conditions
Keywords
Nitric oxide, Nitric oxide dressing, NOx, NOx dressing, Diabetic, Foot, Ulcers, Chronic
Brief summary
This is a 2 part study to assess the safety and efficacy of a nitric oxide (NOx) generating dressing on chronic diabetic foot ulcers (DFU). Nitric oxide has a range of effects on the body including vasodilation and angiogenesis. It is also a potent antimicrobial. This 140 patient, randomised, controlled clinical study will assess the ability of a simple 2 part, NOx generating dressing to increase blood flow in DFUs and to improve healing in chronic DFUs compared to standard of care.
Detailed description
This is a clinical study of a new wound dressing for diabetic foot ulcers (DFU). The dressing consists of 2 stable layers that when placed together release Nitric Oxide. In preclinical studies NOx delivery has caused significant vasodilation, angiogenesis and demonstrated potent anti-microbial activity. In part 1 of the study, the dressing will be applied to up to 20 DFUs for a set period and the blood flow in and around the wound will be measured before and after application of the dressing. Any adverse events will be recorded. If an increase in blood flow is seen and the dressing is well tolerated, part 2 will begin, which is a multi-centre, 120 patient, randomised, controlled study. 60 patients with chronic DFUs will be treated with the NOx generating dressing and 60 patients will continue to receive standard of care. The efficacy and the tolerability of the dressing will be measured. The NOx dressing will be changed at least every 2 days and the standard of care changed as in normal clinical practice. At weekly clinical visits the diameter, area and volume of the wound will be measured. The infective status of the wound will be assessed and the inflammatory profile of the wound will be measured.
Interventions
DEVICENOx dressing
The NOx dressing should be changed at least every 2 days.
OTHERStandard of Care
The clinician/podiatrist is free to use whichever treatment they would choose to use on the patient in their current clinical practice.
Sponsors
Queen Mary University of London
Edixomed Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients aged over 18 years. * Diagnosed with type 1 or type 2 diabetes. * With a chronic (present for at least 6 weeks) full-thickness foot ulcer (on or below the malleoli) not penetrating to tendon, periosteum or bone, and with a cross-sectional area between 25 and 2500 mm2. * Patients must have pedal blood flow between normal and moderately ischaemic. Measurable as a palpable pedal pulse or in the absence of a palpable pedal pulse they must have a TcPO2 of ≥30mmHg or an ABPI of between 0.5-1.00, or \> 1.2. (An ABPI of \>1.2 is associated with calcification rather than ischaemia. We are including patients with an ABPI \>1.2 because ABPI is measured in large arteries. NOx has the ability to dilate medium to small arterioles which are less likely to be calcified.) * With some degree of neuropathy (as commonly seen in the Diabetes Foot Clinic). * Able to read and understand the Volunteer Information Sheet and to provide meaningful written informed consent. * Able and willing to follow the Protocol requirements.
Exclusion criteria
* Female patients who are pregnant or breast-feeding * Any other serious disease likely to compromise the outcome of the trial * Participation in any clinical study during the eight (8) weeks preceding the dosing period of the study * Wound area greater than 2500 square mm; * Patients with severe ischaemia. Measurable as absence of palpable pedal pulse and a TcPO2 of less than 30mmhg, or ABPI \< 0.5 or between 1.0-1.2.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure the safety of the NOx generating dressing | Monitored at every visit until 12 weeks or ulcer is healed and at 3 month post treatment followed | Number of participants with adverse events during the active study period and the following 3 months post treatment |
| Measure the efficacy of the NOx generating dressing | Measured at every patient visit until healed or 12 weeks of treatment is reached | The time to healing of the ulcer will be measured and compared between the NOx generating dressing arm and the standard of care arm |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measure changes in ulcer blood flow. | 3 months | In Part 1 of the study, blood flow in the ulcer will be measured by laser Doppler fluximetry before and after the NOx generating dressing is applied. |
| Measure changes in the inflammatory/infective status of the wounds. | Samples taken at every visit until 12 weeks or the ulcer is healed | Samples taken at every visit will be measured for microbial content and inflammatory cytokine presence and a comparison made between the 2 arms. |
| Measure the rate of repeat ulcers and breakdown in healing. | 1 year | — |
Countries
United Kingdom
Outcome results
None listed